Heterocyclic substituted indolinones
    3.
    发明授权
    Heterocyclic substituted indolinones 失效
    杂环取代的二氢吲哚酮

    公开(公告)号:US4870077A

    公开(公告)日:1989-09-26

    申请号:US94871

    申请日:1987-09-10

    摘要: Heterocyclic substituted indolinones of the formula: ##STR1## wherein R.sub.1 is a hydrogen atom or an alkyl or hydroxyalkyl radical, R.sub.2 is a carboxyl group or an alkoxy-carbonyl, hydroxyalkyl or alkylcarbonyloxyalkyl radical or R.sub.1 and R.sub.2, together with the carbon atom to which they are attached, form a lactone having 4, 5 or 6 ring atoms, A-B is --CH.sub.2 --CH(R.sub.3)--, --CH.dbd.CR.sub.3 --, --CH.sub.2 --NH--, --NH--CH.sub.2 --, --CH.sub.2 --O--, --O--CH.sub.2 --, --CH.sub.2 --S-- or --S--CH.sub.2 -- radical, R.sub.3 being a hydrogen atom or an alkyl or hydroxyalkyl radical, or A is a valency bond and B is a methylene radical ##STR2## or an imino group ##STR3## R.sub.4, R.sub.5, and R.sub.6 independently being hydrogen atoms or alkyl radicals wherein the alkyl groups independently contain 1 to 6 carbon atoms; as well as the tautomers thereof and the physiologically acceptable salt thereof and the physiologically acceptable salts thereof with inorganic and organic acids, are disclosed, such as, for instance, the compound 5-(2,3,4,5-tetrahydro-3-oxopyridazin-6-yl)-3-ethoxycarbonyl-3-methyl-1H-indol n-2-one. The compounds of the invention are useful in the treatment of heart and circulatory diseases, for example, by producing a positive inotropic action in a patient to whom the compounds are administered.

    摘要翻译: 式(I)的杂环取代的二氢吲哚酮:其中R 1是氢原子或烷基或羟烷基,R 2是羧基或烷氧羰基,羟基烷基或烷基羰基氧基烷基或R 1和R 2与碳 它们连接的原子形成具有4,5或6个环原子的内酯,AB是-CH 2 -CH(R 3) - , - CH = CR 3 - , - CH 2 -NH-,-NH-CH 2 - , - CH 2 -O-,-O-CH 2 - , - CH 2 -S-或-S-CH 2 - 基,R 3是氢原子或烷基或羟烷基,或A是价键,B是亚甲基。 或亚氨基基团R4,R5和R6独立地为氢原子或烷基,其中烷基独立地含有1至6个碳原子; 以及其与无机和有机酸的互变异构体及其生理上可接受的盐及其生理上可接受的盐,例如化合物5-(2,3,4,5-四氢-3- 氧基哒嗪-6-基)-3-乙氧基羰基-3-甲基-1H-吲哚-2-酮。 本发明的化合物可用于治疗心脏和循环系统疾病,例如通过在施用化合物的患者中产生正性肌力作用。

    Pyridazinone derivatives, and pharmaceutical compositions containing them
    5.
    发明授权
    Pyridazinone derivatives, and pharmaceutical compositions containing them 失效
    哒嗪酮衍生物和含有它们的药物组合物

    公开(公告)号:US4847251A

    公开(公告)日:1989-07-11

    申请号:US80998

    申请日:1987-08-03

    摘要: The present invention provides pyridazinone derivatives of the general formula: ##STR1## wherein Het is a mono- or bicyclic heterocycle with one or two nitrogen atoms, B-C is a --CHR.sub.1 --CH.sub.2 --, --CR.sub.1 .dbd.CH--, --CHR.sub.1 --O--, --O--CHR.sub.1 --, --CHR.sub.1 --NH-- or --NH--CHR.sub.1 -- group, R.sub.1 being a hydrogen atom or an alkyl radical, and A is an amiono, alkylcarbonylamino, aminocarbonylamino, aminothiocarbonylamino, alkylaminothiocarbonylamino, alkylamionocarbonylamino, N'-cyanoguanidino or N'-cyano-N"-alkylguanidino group, a substituted phenyl ring or heterocycle attached via a nitrogen or sulphur atom, or a mono- or bicyclic substituted heterocycle with 1 to 3 nitrogen atoms, one ring nitrogen atom being directly attached to Het; as well as the physiologically acceptable salts thereof.The present invention also provides processes for the preparation of these pyridazinone drivatives and pharmaceutical compositions containing them for the treatment of heart and circulatory diseases.

    摘要翻译: 本发明提供以下通式的哒嗪酮衍生物:其中Het是具有一个或两个氮原子的单环或双环杂环,BC是-CHR 1 -CH 2 - ,-CR 1 = CH-,-CHR 1 -O-,-O-CHR 1 - , - CHR 1 -NH-或-NH-CHR 1 - 基,R 1为氢原子或烷基,A为酰胺基,烷基羰基氨基,氨基羰基氨基,氨基硫代羰基氨基,烷基氨基硫代羰基氨基,烷基氨基羰基氨基,N “氰基胍基”或“氰基-N” - 烷基胍基,经氮或硫原子连接的取代苯环或杂环,或具有1至3个氮原子的单环或双环取代杂环,一个环氮原子为 直接附于Het; 以及其生理上可接受的盐。 本发明还提供了制备这些哒嗪酮驱动剂和含有它们用于治疗心脏和循环系统疾病的药物组合物的方法。

    Tricyclic benzotriazoles, processes for the preparation thereof and
pharmaceutical compositions containing them
    6.
    发明授权
    Tricyclic benzotriazoles, processes for the preparation thereof and pharmaceutical compositions containing them 失效
    三环苯并三唑,其制备方法和含有它们的药物组合物

    公开(公告)号:US4835167A

    公开(公告)日:1989-05-30

    申请号:US80658

    申请日:1987-08-03

    摘要: The present invention provides new tricyclic benzotriazoles of the general formula: ##STR1## wherein Z is a hydrogen atom or an acyl radical, Y is an oxygen or sulphur atom or two hydrogen atoms and X is an oxygen or sulphur atom or a >CR.sub.1 R.sub.2 or >NR.sub.3 group, R.sub.1 is a hydrogen atom or an alkyl, alkenyl or cycloalkyl radical, R.sub.2 is a hydrogen atom or an alkyl, alkenyl or cyano group or a carbonyl group substituted by a hydroxyl, alkyl, alkoxy, amino, alkylamino, dialkylamino or hydrazino group or R.sub.2, together with R.sub.1, represents a cycloalkylene radical or R.sub.1 and R.sub.2 together form an alkylidene or cycloalkylidene radical and R.sub.3 is a hydrogen atom or an alkyl radical; the tautomers thereof and the physiologically acceptable acid-addition salts thereof with inorganic and organic acids.The present invention also provides processes for the preparation of these tricyclic benzotriazoles and pharmaceutical compositions containing them for the treatment of heart and circulatory diseases.

    摘要翻译: 本发明提供了新的具有以下通式的三环苯并三唑:其中Z是氢原子或酰基,Y是氧或硫原子或两个氢原子,X是氧或硫原子或 > CR1R2或> NR3基团,R1是氢原子或烷基,烯基或环烷基,R2是氢原子或烷基,烯基或氰基或被羟基,烷基,烷氧基,氨基,烷基氨基取代的羰基 ,二烷基氨基或肼基或R 2与R 1一起代表亚环烷基或R 1和R 2一起形成亚烷基或亚环烷基,R 3为氢原子或烷基; 其互变异构体及其与无机和有机酸的生理上可接受的酸加成盐。 本发明还提供了制备这些三环苯并三唑的方法和含有它们用于治疗心脏和循环系统疾病的药物组合物。

    4-aminopyridazines, method of preparing them and drugs containing these
compounds
    9.
    发明授权
    4-aminopyridazines, method of preparing them and drugs containing these compounds 失效
    4-氨基哒嗪,其制备方法和含有这些化合物的药物

    公开(公告)号:US5795892A

    公开(公告)日:1998-08-18

    申请号:US793445

    申请日:1997-02-28

    摘要: The invention concerns new 4-aminopyridazines of the general formula I ##STR1## in which R.sup.1 denotes an R.sup.2 --SO.sub.2 --O-- or R.sup.2 --SO.sub.2 --NR.sup.3 -- group in which R.sup.2 denotes a cycloalkyl residue, an unsubstituted or substituted aryl or heteroaryl residue, R.sup.3 denotes a hydrogen atom, an alkyl or alkyloxyalkyl group which can be unsubstituted or substituted once or several times by hydroxy groups wherein the hydroxy groups can be substituted by alkyl, hydroxyalkyl, alkyloxyalkyl, hydroxyalkyloxyalkyl or alkylcarbonyl groups and wherein in each case two vicinal hydroxy groups can be linked together by alkylidene groups, as well as hydrates, solvates and physiologically tolerated salts thereof. The invention also concerns the optically active forms, racemates and mixtures of diastereomers of these compounds, processes for their production and pharmaceutical agents containing these compounds having a thrombin-inhibiting action.

    摘要翻译: PCT No.PCT / EP95 / 03383 Sec。 371日期1997年2月28日 102(e)日期1997年2月28日PCT 1995年8月26日PCT PCT。 公开号WO96 / 06832 日期1996年3月7日本发明涉及通式Ⅰ(I)的新的4-氨基哒嗪,其中R1表示R2-SO2-O-或R2-SO2-NR3-基团,其中R2表示环烷基残基, 未取代或取代的芳基或杂芳基残基,R3表示氢原子,烷基或烷氧基烷基,其可以是未取代的或被羟基取代一次或几次,其中羟基可以被烷基,羟烷基,烷氧基烷基,羟基烷氧基烷基或烷基羰基 基团,并且其中在每种情况下,两个邻位羟基可以通过亚烷基连接在一起,以及其水合物,溶剂化物和生理上耐受的盐。 本发明还涉及这些化合物的光学活性形式,外消旋物和非对映异构体的混合物,其制备方法和含有这些具有凝血酶抑制作用的化合物的药剂。

    2-bicyclobenzimidazoles, processes for their preparation and medicaments
containing these compounds
    10.
    发明授权
    2-bicyclobenzimidazoles, processes for their preparation and medicaments containing these compounds 失效
    2-二环苯并咪唑,它们的制备方法和含有这些化合物的药物

    公开(公告)号:US5414088A

    公开(公告)日:1995-05-09

    申请号:US847060

    申请日:1992-04-14

    摘要: The invention concerns compounds of formula I ##STR1## where R.sup.1 is hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl or C.sub.3 -C.sub.7 -cycloalkyl, R.sup.2 is C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, cyano, carboxy [carbonyl substituted by hydroxyl], C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkoxy, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino or hydrazino or R.sup.1 and R.sup.2 together are C.sub.2 -C.sub.6 -alkylidene or C.sub.3 -C.sub.6 -cycloalkylidene or R.sup.1 and R.sup.2, together with the carbon atoms to which they are attached, form a C.sub.3 -C.sub.7 -spirocycle, n is 0 or 1, R.sup.3 is hydrogen, C.sub.1 -C.sub.8 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, C.sub.3 -C.sub.7 -cycloalkyl, benzyl, carboxy-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkyloxycarbonyl-C.sub.1 -C.sub.6 -alkyl or di-C.sub.1 -C.sub.6 -alkyloxophosphinyl-C.sub.1 -C.sub.6 -alkyl and R.sup.4 -R.sup. 6 are as in the specification. These compounds of formula I serve for the preparation of medicaments to inhibit erythrocyte and thrombocyte aggregation. Therefore, these compounds are useful for the treatment of diseases where these aggregations occur such as arterial occlusive or ischaemic conditions, venous insufficiency or diabetes mellitus.

    摘要翻译: PCT No.PCT / EP90 / 01663 Sec。 371日期:1992年4月14日 102(e)日期1992年4月14日PCT 1990年9月4日PCT PCT。 出版物WO91 / 04974 1991年4月18日,本发明涉及式I化合物(Ⅰ)其中R1是氢,C1-C6-烷基,C2-C6-烯基或C3-C7-环烷基,R2是C1-C6-烷基 ,C 2 -C 6 - 烯基,氰基,羧基[被羟基取代的羰基],C 1 -C 6 - 烷基,C 1 -C 6 - 烷氧基,氨基,C 1 -C 6 - 烷基氨基,二-C 1 -C 6烷基氨基或肼基或R 1和R 2 一起是C 2 -C 6亚烷基或C 3 -C 6亚环烷基或R 1和R 2与它们连接的碳原子一起形成C 3 -C 7 - 螺环,n是0或1,R 3是氢,C 1 -C 8 - 烷基,C 2 -C 6 - 烯基,C 2 -C 6 - 炔基,C 3 -C 7 - 环烷基,苄基,羧基-C 1 -C 6 - 烷基,C 1 -C 6 - 烷氧基羰基-C 1 -C 6烷基或二-C 1 -C 6烷氧基氧膦 -C 1 -C 6烷基和R 4 -R 6如说明书中所述。 这些式I化合物用于制备抑制红细胞和血小板聚集的药物。 因此,这些化合物可用于治疗发生这些聚集的疾病,例如动脉闭塞或缺血性疾病,静脉功能不全或糖尿病。